Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHLEY CAUTHEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1720254071
CMS profile
1307330
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$17,142.64

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHLEY CAUTHEN

NPI 1720254071 · CMS profile ID 1307330

Allopathic & Osteopathic Physicians / Dermatology

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720254071?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720254071?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720254071?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1720254071?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $17,142.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $8.8002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927124843 CMS
Lilly USA, LLC $17.2502/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917887013 CMS
ABBVIE INC. $18.7302/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890721593 CMS
Janssen Biotech, Inc. $19.9702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885714423 CMS
LEO Pharma Inc. $15.7201/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936206337 CMS
ABBVIE INC. $22.4601/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890721591 CMS
ABBVIE INC. $4.8001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890721589 CMS
ABBVIE INC. $18.0201/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890721587 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44,715.90 167
PY2020 $20,828.89 113
PY2021 $40,360.15 162
PY2022 $17,142.64 108
PY2023 $34,755.77 142
PY2024 $39,636.60 158
PY2025 $90,991.23 184

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,444.82 1
PY2025 Principal investigator $782,109.75 232
PY2024 Recipient $114.46 1
PY2024 Principal investigator $614,925.76 288
PY2023 Principal investigator $146,927.36 51
PY2022 Principal investigator $211,308.04 59
PY2021 Recipient $500.00 1
PY2021 Principal investigator $442,861.62 55
PY2020 Recipient $1,692.00 1
PY2020 Principal investigator $453,418.14 69
PY2019 Recipient $53,215.00 5
PY2019 Principal investigator $1,449,298.77 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

233 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,742.00 12/19/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394485
Principal investigator 1 Incyte Corporation $1,903.20 12/08/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582087
Principal investigator 1 Incyte Corporation $7,850.00 12/04/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240582059
Principal investigator 1 Incyte Corporation $1,800.00 12/04/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240582063
Principal investigator 1 Incyte Corporation $1,250.00 12/04/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240582067
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582079
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582083
Principal investigator 1 Incyte Corporation $33.18 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582089
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582093
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582098
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582105
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,484.19 12/01/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289063
Principal investigator 1 Incyte Corporation $1,808.80 11/24/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582071
Recipient Eli Lilly and Company $2,444.82 11/10/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE ATOPIC DERMATITIS AND HIGH ITCH BURDEN No dispute reported 06/30/2026 1187873827
Principal investigator 1 ABBVIE INC. $6,804.53 11/05/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521405
Principal investigator 1 Janssen Research & Development, LLC $1,871.00 11/03/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394540
Principal investigator 1 Eli Lilly and Company $5,074.05 10/27/2025 Non-covered Recipient Entity
RENSTAR INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187888226
Principal investigator 1 Eli Lilly and Company $482.25 10/27/2025 Non-covered Recipient Entity
RENSTAR INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187888228
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 10/21/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287147
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,122.11 10/21/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287151
Principal investigator 1 Incyte Corporation $2,825.00 10/20/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582103
Principal investigator 1 Incyte Corporation $294.80 10/20/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582110
Principal investigator 1 ABBVIE INC. $102.60 10/14/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516713
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,717.00 10/13/2025 Non-covered Recipient Entity
RENSTAR
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246434163
Principal investigator 1 ABBVIE INC. $7,760.76 10/09/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515915
Principal investigator 1 Incyte Corporation $2,489.00 10/08/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582074
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 10/07/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $250.00 10/07/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223286423
Principal investigator 1 Janssen Research & Development, LLC $350.00 10/06/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394558
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,881.70 10/01/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286079
Principal investigator 1 ABBVIE INC. $1,100.00 09/23/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511902
Principal investigator 1 Janssen Research & Development, LLC $3,526.00 09/22/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394517
Principal investigator 1 ABBVIE INC. $255.69 09/18/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511494
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,450.00 09/18/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285700
Principal investigator 1 Incyte Corporation $117.00 09/17/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581995
Principal investigator 1 Incyte Corporation $89.00 09/17/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582002
Principal investigator 1 Incyte Corporation $160.00 09/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581989
Principal investigator 1 Incyte Corporation $4,000.00 09/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581999
Principal investigator 1 Incyte Corporation $800.00 09/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582010
Principal investigator 1 Incyte Corporation $1,100.00 09/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582044
Principal investigator 1 ABBVIE INC. $1,100.00 09/11/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510698
Principal investigator 1 Incyte Corporation $1,638.40 09/10/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581971
Principal investigator 1 Incyte Corporation $1,945.00 09/10/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581973
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/08/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394523
Principal investigator 1 ABBVIE INC. $6,210.56 09/04/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509378
Principal investigator 1 Janssen Research & Development, LLC $100.00 09/04/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394491
Principal investigator 1 Incyte Corporation $622.70 09/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582031
Principal investigator 1 Incyte Corporation $591.30 09/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582033
Principal investigator 1 Incyte Corporation $4.86 09/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582038
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,098.45 09/02/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284779
Principal investigator 1 Janssen Research & Development, LLC $7,550.00 09/01/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394528
Principal investigator 1 ABBVIE INC. $550.00 08/26/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505793
Principal investigator 1 ABBVIE INC. $3,065.00 08/26/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505795
Principal investigator 1 Janssen Research & Development, LLC $5,456.00 08/25/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394456
Principal investigator 1 ABBVIE INC. $2,750.00 08/22/2025 Non-covered Recipient Entity
RENSTAR LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202505605
Principal investigator 1 ABBVIE INC. $5,991.00 08/22/2025 Non-covered Recipient Entity
RENSTAR LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202505607
Principal investigator 1 ABBVIE INC. $2,200.00 08/22/2025 Non-covered Recipient Entity
RENSTAR LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202505613
Principal investigator 1 Incyte Corporation $1,584.90 08/20/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581962
Principal investigator 1 Incyte Corporation $1,761.00 08/20/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581967
Principal investigator 1 ABBVIE INC. $1,100.00 08/12/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202504247
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $850.00 08/12/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 08/12/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284105
Principal investigator 1 Eli Lilly and Company $5,767.53 08/08/2025 Non-covered Recipient Entity
RENSTAR INC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187888400
Principal investigator 1 ABBVIE INC. $29,872.91 08/06/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502795
Principal investigator 1 Incyte Corporation $22.90 08/06/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582028
Principal investigator 1 ABBVIE INC. $4,572.25 08/05/2025 Non-covered Recipient Entity
RENSTAR LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202501526
Principal investigator 1 Incyte Corporation $1,350.00 08/04/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581985
Principal investigator 1 Incyte Corporation $1,735.65 08/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581981
Principal investigator 1 Janssen Research & Development, LLC $2,728.00 08/01/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,736.65 08/01/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,159.24 08/01/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283735
Principal investigator 1 Janssen Research & Development, LLC $2,615.00 07/21/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394467
Principal investigator 1 Incyte Corporation $1,672.95 07/18/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582041
Principal investigator 1 Incyte Corporation $39.00 07/09/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581957
Principal investigator 1 Incyte Corporation $2,620.00 07/09/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581977
Principal investigator 1 ABBVIE INC. $550.00 07/08/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202497388
Principal investigator 1 ABBVIE INC. $10,140.28 07/02/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496241
Principal investigator 1 ABBVIE INC. $5,000.00 07/02/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496243
Principal investigator 1 Incyte Corporation $129.44 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582006
Principal investigator 1 Incyte Corporation $206.10 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582015
Principal investigator 1 Incyte Corporation $26.50 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582017
Principal investigator 1 Incyte Corporation $148.08 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582021
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582024
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582048
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582051
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240582055
Principal investigator 1 Janssen Research & Development, LLC $192.00 06/30/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394511
Principal investigator 1 Incyte Corporation $1,808.80 06/25/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581855
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 06/23/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394473
Principal investigator 1 Incyte Corporation $1,644.30 06/11/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581882
Principal investigator 1 Incyte Corporation $1,827.00 06/11/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28,923.42 06/05/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280798
Principal investigator 1 ABBVIE INC. $2,111.50 06/03/2025 Non-covered Recipient Entity
RENSTAR LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202489137
Principal investigator 1 ABBVIE INC. $5,167.61 06/03/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489139
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581877
Principal investigator 1 Incyte Corporation $249.08 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581889
Principal investigator 1 Incyte Corporation $295.65 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581893
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581900
Principal investigator 1 Incyte Corporation $24.30 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581908
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581944
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581949
Principal investigator 1 Eli Lilly and Company $97,460.95 06/02/2025 Non-covered Recipient Entity
RENSTAR INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187889124
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 05/29/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394553
Principal investigator 1 Janssen Research & Development, LLC $9,234.00 05/26/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394535
Principal investigator 1 Incyte Corporation $2,825.00 05/21/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581834
Principal investigator 1 Incyte Corporation $1,904.00 05/21/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581837
Principal investigator 1 Incyte Corporation $1,436.50 05/21/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581937
Principal investigator 1 ABBVIE INC. $11,287.72 05/07/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482451
Principal investigator 1 Incyte Corporation $1,937.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581808
Principal investigator 1 Incyte Corporation $150.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581823
Principal investigator 1 Incyte Corporation $1,827.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581840
Principal investigator 1 Incyte Corporation $1,088.10 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581843
Principal investigator 1 Incyte Corporation $459.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581847
Principal investigator 1 Incyte Corporation $276.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581852
Principal investigator 1 Incyte Corporation $78.20 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581863
Principal investigator 1 Incyte Corporation $1.86 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581896
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581904
Principal investigator 1 Incyte Corporation $103.05 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581913
Principal investigator 1 Incyte Corporation $1,350.00 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581918
Principal investigator 1 Incyte Corporation $56.73 05/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581933
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,225.00 05/02/2025 Non-covered Recipient Entity
RENSTAR
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246434154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $842.40 05/01/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278770
Principal investigator 1 Janssen Research & Development, LLC $4,248.00 04/28/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394499
Principal investigator 1 Incyte Corporation $130.00 04/25/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581825
Principal investigator 1 Incyte Corporation $490.00 04/25/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581830
Principal investigator 1 Eli Lilly and Company $4,044.08 04/23/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187890614
Principal investigator 1 Incyte Corporation $4,000.00 04/23/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581804
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,000.00 04/18/2025 Non-covered Recipient Entity
RENSTAR
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246434159
Principal investigator 1 Janssen Research & Development, LLC $15,350.00 04/11/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 04/10/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277816
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,739.11 04/10/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277824
Principal investigator 1 Incyte Corporation $2,620.00 04/09/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581813
Principal investigator 1 Incyte Corporation $1,513.30 04/09/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581921
Principal investigator 1 Incyte Corporation $1,827.00 04/09/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581925
Principal investigator 1 Incyte Corporation $4,050.00 04/07/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581800
Principal investigator 1 Incyte Corporation $800.00 04/07/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581868
Principal investigator 1 Incyte Corporation $1,350.00 04/07/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581885
Principal investigator 1 Incyte Corporation $550.00 04/07/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581929
Principal investigator 1 Incyte Corporation $4,000.00 04/07/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581941
Principal investigator 1 ABBVIE INC. $6,464.40 04/03/2025 Non-covered Recipient Entity
RENSTAR LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202472786
Principal investigator 1 Incyte Corporation $1,672.95 04/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581817
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581859
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,696.30 03/25/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277019
Principal investigator 1 Incyte Corporation $1,827.00 03/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581559
Principal investigator 1 Incyte Corporation $1,875.15 03/12/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581575
Principal investigator 1 ABBVIE INC. $14,959.54 03/07/2025 Non-covered Recipient Entity
RENSTAR LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460889
Principal investigator 1 ABBVIE INC. $1,826.65 03/07/2025 Non-covered Recipient Entity
RENSTAR LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202460893
Principal investigator 1 Eli Lilly and Company $27,125.11 03/06/2025 Non-covered Recipient Entity
RENSTAR INC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187890374
Principal investigator 1 Incyte Corporation $48.54 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581651
Principal investigator 1 Incyte Corporation $91.60 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581655
Principal investigator 1 Incyte Corporation $236.52 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581660
Principal investigator 1 Incyte Corporation $311.35 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581664
Principal investigator 1 Incyte Corporation $98.72 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581669
Principal investigator 1 Incyte Corporation $622.70 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581671
Principal investigator 1 Incyte Corporation $6.36 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581675
Principal investigator 1 Incyte Corporation $22.90 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581682
Principal investigator 1 Incyte Corporation $0.31 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581685
Principal investigator 1 Incyte Corporation $311.35 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581691
Principal investigator 1 Incyte Corporation $21.87 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581695
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581699
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581703
Principal investigator 1 Incyte Corporation $2.43 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581706
Principal investigator 1 Incyte Corporation $1.24 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581711
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581754
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581759
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581762
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581766
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581770
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581775
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581779
Principal investigator 1 Janssen Research & Development, LLC $2,124.00 03/03/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,561.46 02/25/2025 Non-covered Recipient Entity
RENSTAR LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275531
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,735.48 02/20/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275427
Principal investigator 1 Incyte Corporation $2,070.00 02/10/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581523
Principal investigator 1 Incyte Corporation $1,926.00 02/10/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581527
Principal investigator 1 Incyte Corporation $1,535.85 02/10/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581715
Principal investigator 1 Janssen Research & Development, LLC $12,328.00 02/07/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175394546
Principal investigator 1 ABBVIE INC. $1,644.50 02/06/2025 Non-covered Recipient Entity
RENSTAR LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447417
Principal investigator 1 ABBVIE INC. $14,895.24 02/06/2025 Non-covered Recipient Entity
RENSTAR LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,044.66 02/04/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274751
Principal investigator 1 Eli Lilly and Company $3,191.10 01/27/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890378
Principal investigator 1 Incyte Corporation $2,741.50 01/27/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581543
Principal investigator 1 Incyte Corporation $1,904.00 01/27/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581599
Principal investigator 1 Eli Lilly and Company $83,819.00 01/21/2025 Non-covered Recipient Entity
RENSTAR INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187889956
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 01/21/2025 Non-covered Recipient Entity
Renstar Llc Renstar Medical Research
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226084667
Principal investigator 1 SANOFI US SERVICES INC. $7,470.00 01/21/2025 Non-covered Recipient Entity
Renstar Llc Renstar Medical Research
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226084671
Principal investigator 1 SANOFI US SERVICES INC. $5,413.00 01/21/2025 Non-covered Recipient Entity
Renstar Llc Renstar Medical Research
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226084674
Principal investigator 1 Janssen Research & Development, LLC $32.00 01/16/2025 Non-covered Recipient Entity
RENSTAR LLC
A Phase 2a2b Multi Center Randomized Placebo and Active Comparator controlled Double Blind Dose ranging Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa. No dispute reported 06/30/2026 1175394504
Principal investigator 1 Incyte Corporation $1,407.30 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581531
Principal investigator 1 Incyte Corporation $1,761.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581536
Principal investigator 1 Incyte Corporation $2,828.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581540
Principal investigator 1 Incyte Corporation $619.05 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581546
Principal investigator 1 Incyte Corporation $1,632.70 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581550
Principal investigator 1 Incyte Corporation $1,966.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581555
Principal investigator 1 Incyte Corporation $1,827.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581609
Principal investigator 1 Incyte Corporation $1,827.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581613
Principal investigator 1 Incyte Corporation $1,761.00 01/15/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,291.36 01/07/2025 Non-covered Recipient Entity
RENSTAR LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273683
Principal investigator 1 ABBVIE INC. $2,914.85 01/02/2025 Non-covered Recipient Entity
RENSTAR LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202433941
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581563
Principal investigator 1 Incyte Corporation $169.60 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581567
Principal investigator 1 Incyte Corporation $307.40 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581571
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581578
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581581
Principal investigator 1 Incyte Corporation $48.42 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581584
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581589
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581595
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581602
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581606
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581616
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581619
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581624
Principal investigator 1 Incyte Corporation $35.02 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581628
Principal investigator 1 Incyte Corporation $123.40 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581631
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581635
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581638
Principal investigator 1 Incyte Corporation $4.12 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581643
Principal investigator 1 Incyte Corporation $4.12 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581647
Principal investigator 1 Incyte Corporation $22.90 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581679
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581718
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581722
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581726
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581729
Principal investigator 1 Incyte Corporation $169.60 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581734
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581739
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581743
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581750
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581784
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581787
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581792
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH OCALA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240581796